Steven W. Kerrigan

Professor of Precision Therapeutics, School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences
Prof. Steve Kerrigan is Deputy Head of the School of Pharmacy (Research), Professor of Precision Therapeutics, Head of the Cardiovascular Infection Research Group which is part of the Irish Centre of Vascular Biology and Co-founder/Chief Scientific Officer at Inthelia Therapeutics (RCSI Spin-out Company).

Prof. Steve Kerrigan is an honours graduate in B.Sc Pharmacology from King's College University of London, UK and obtained an M.Sc in Immunopharmacology from the University of Strathclyde, Glasgow, Scotland. He received a PhD in Cardiovascular Infection specifically investigating platelet-bacterial interactions from RCSI in 2001. Following this he carried out postdoctoral research in the University of California, San Francisco, USA. Prof. Kerrigan was appointed lecturer in Pharmacology in the School of Pharmacy in 2008, promoted to Senior Lecturer in 2013, Associated Professor in 2017 and Full Professor in 2021.

Since his faculty appointment, he has published over 90 articles in leading peer-reviewed international journals and filed 11 patent/disclosures and supervised 21 doctoral candidates to completion as primary supervisor. He has a current h-index of 37. Accolades include a Health Research Board Training Fellowship, Science Foundation Ireland Career Development Award and Enterprise Ireland Commercialization Fund. He has presented over 60 invited talks at national and international universities, conferences and symposia including International Society for Thrombosis and Haemostasis, Platelets International Symposium, American Society for Microbiology and the European Shock Society. He has served as an invited reviewer for more than 40 scientific journals and served as a grant reviewer for various international funding bodies. Prof. Kerrigan is a member of more than 10 international societies and was elected to Chartered status (CBiol) and Fellowship of the Society of Biology (FSB) which are the highest grades of membership of the professional body. Prof. Kerrigan was previously co-chair of the International Society for Thrombosis and Haemostasis Scientific Standardization Committee in Biorheology, committee member in the European Sepsis Alliance research working group and is currently a member of the Royal Irish Academy (RIA) Life and Medical Sciences Multidisciplinary Committee.

Prof. Kerrigan has received several awards for his groundbreaking research discoveries that are now progressing to trials. These accolades include the 2023 Science Foundation Ireland Innovation Award and the 2024 Future Health Summit Innovation Award.